Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 08/24 09:24:54 pm
118.81 USD   -0.53%
08/22 FOR U.S. MEDIA : Janssen Announces 25 Presentations at Upcoming ESC..
08/21 JOHNSON & JOHNS : With B.good, healthy eating comes to King of Pruss..
08/21 JOHNSON & JOHNS : Going from big pharma to farm-fresh
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA Approves J&J's Drug for Tough-to-Treat Tuberculosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/31/2012 | 08:19pm CEST

--FDA approves J&J's Sirturo but requires prominent warning label

--Drug is unlikely to be a big moneymaker but may accrue goodwill to J&J

--Fewer than 100 Americans suffer from the disease, multidrug resistant TB

(Adds details on safety risks in paragraph eight, and comments from consumer group Public Citizen and FDA official in paragraphs 13-16.)

 
   By Joseph Walker and Nathalie Tadena 
 

The U.S. Food and Drug Administration approved Johnson & Johnson's (JNJ) drug to treat a form of resistant tuberculosis that is uncommon in the U.S. but growing globally.

The drug, Sirturo, will treat patients with multidrug resistant tuberculosis, or MDR-TB, a possibly fatal disease that affects as many as 630,000 people world-wide who can't be cured with existing therapies alone. Tuberculosis is a bacterial infection that mostly involves the lungs.

Sirturo, also known as bedaquiline, is not expected to be a large moneymaker for Johnson & Johnson (JNJ), one of the world's largest health-care conglomerate, because the disease is prevalent in poorer countries unable to afford high prices for the treatment. Providing the drug, though, could help the company create goodwill among regulators, governments and patients around the world.

"The commercial opportunity is very limited," said Pamela Van Houten, a J&J spokesperson. "This is part of our commitment to advance innovative medicines that help address serious public health issues."

The company said it expects to begin selling Sirturo in the second quarter of 2013, and won't announce its sales price until then. Fewer than 100 Americans have MDR-TB, according to J&J, but FDA approval is likely to strengthen the chances for approval in regions where the disease is more prevalent, including India, China and Eastern Europe.

However, the drug's potential side effects, including an increased risk of death, has raised concerns among members of the FDA. The agency will require that a prominent warning label be placed on the drug, informing consumers that patients taking Sirturo in clinical trials saw increased rates of fatalities.

"Because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don't have other treatment options," said Edward Cox, an FDA official.

About 11.4% of patients taking Sirturo died in during clinical trials, compared to 2.5% taking placebos.

The FDA granted Sirturo accelerated approval, which is a type of temporary approval for diseases that don't have viable treatment options, based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group.

It is still unclear, though, whether Sirturo caused the increase death rate, said Mel Spigelman, chief executive of the Global Alliance for TB Drug Development, which is partnering with J&J to develop Sirturo in more common strains of tuberculosis.

"It looked more likely that this was just a bad coincidence," Dr. Spigelman said. "But you have to be careful, and the monitoring will have to be rigorous."

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether Sirturo played a role in deaths seen in clinical studies.

"A greater number of deaths in the bedaquiline arm is concerning," FDA Deputy Director of Anti-Infective Products, said in a presentation to the panel. "The role of bedaquiline in deaths where hepatoxocity and cardiac failure are contributory could not be ruled out."

The consumer group Public Citizen, which had been strongly opposed to approval, said Monday that it was disappointed in the FDA's decision.

"There were five times more deaths in the drug group than in the placebo group," said Sidney Wolfe, director of health research at Public Citizen. "I don't see how [the FDA] can be so dismissive about it."

Tuberculosis usually is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Some forms of tuberculosis, however, can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the world-wide control of tuberculosis."

Sirturo is designed to work in a new way to treat tuberculosis and would be used with other drugs.

Shares of J&J rose 27 cents to $69.75.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/22 FOR U.S. MEDIA ONLY : Janssen Announces 25 Presentations at Upcoming ESC Congres..
08/21 JOHNSON & JOHNSON : With B.good, healthy eating comes to King of Prussia
08/21 JOHNSON & JOHNSON : Going from big pharma to farm-fresh
08/19 JOHNSON & JOHNSON : Diabetes Selfcare Demands Retail, Health Care Collaboration ..
08/19 JOHNSON & JOHNSON : ex-dividend day
08/18 JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA to Expand Indication..
08/18 JOHNSON & JOHNSON : Frost & Sullivan MindXChange Reveals How Organizations Can L..
08/18 JOHNSON & JOHNSON : Announces Ruling Related to REMICADE in the District of Mass..
08/18 JOHNSON & JOHNSON : Patanjali enters babycare segment
08/17 JOHNSON & JOHNSON : Patent for J&J's Remicade invalidated, cheaper version looms
More news
Sector news : Pharmaceuticals - NEC
11:34aDJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
10:32aDJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
10:15aDJPfizer Buys Part of AstraZeneca's Antibiotics Business
09:03aDJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:53p Build A Profitable Dividend Growth Investing Portfolio From Scratch (Podcast ..
10:18a PFIZER-MEDIVATION DEAL : Good Or Bad For Shareholders?
07:53a When Can Portola's Drug Be Approved, And How Much Does It Matter?
06:14a JOHNSON & JOHNSON : Don't Let High P/Es Panic You Into Selling
02:20a Looking At Top 5 Stocks In S&P 500 - Market Cap / Earnings Weight Influence O..
Advertisement
Financials ($)
Sales 2016 72 068 M
EBIT 2016 21 808 M
Net income 2016 16 515 M
Finance 2016 13 074 M
Yield 2016 2,62%
P/E ratio 2016 20,33
P/E ratio 2017 17,96
EV / Sales 2016 4,35x
EV / Sales 2017 4,06x
Capitalization 326 773 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 6,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON16.28%326 773
ROCHE HOLDING LTD.-12.26%219 257
NOVARTIS AG-9.97%214 603
PFIZER INC.8.71%212 844
MERCK & CO., INC.20.37%175 812
GLAXOSMITHKLINE PLC21.19%106 755
More Results